Shorter Romosozumab Course Works as Well as 12-Month Regimen

Published Date: 19 Jun 2026

A 3-month course of romosozumab followed by denosumab produced bone density gains comparable to those of the standard 12-month regimen in postmenopausal women at high fracture risk.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More men with prostate cancer are avoiding unnecessary surgery

2.

Even when they are not paying attention, children are still learning.

3.

FDA Approves New Bladder Cancer First-Line Standard of Care.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

AI is useful in low-resource areas for triaging breast masses.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot